Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGRXNASDAQ:ARTVNASDAQ:ITRMNASDAQ:LIAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shs120,938 shsARTVArtiva Biotherapeutics$1.60-0.6%$2.07$1.55▼$17.31$39.22MN/A172,463 shs97,786 shsITRMIterum Therapeutics$1.03+4.7%$1.02$0.81▼$3.02$39.35M2.781.06 million shs1.19 million shsLIANLianBio$0.42+1.2%$0.30$0.27▼$4.99$44.85M0.231.04 million shs595,904 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRXAgile Therapeutics0.00%0.00%0.00%0.00%+353.45%ARTVArtiva Biotherapeutics-0.62%-10.56%-17.44%-55.77%+160,999,900.00%ITRMIterum Therapeutics+4.14%+0.38%+5.57%-26.04%-15.92%LIANLianBio+7.84%+8.04%+13.87%+109.83%+32.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGRXAgile TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AARTVArtiva Biotherapeutics2.1966 of 5 stars3.50.00.00.00.61.71.3ITRMIterum Therapeutics1.9462 of 5 stars3.55.00.00.00.60.00.0LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGRXAgile Therapeutics 0.00N/AN/AN/AARTVArtiva Biotherapeutics 3.00Buy$17.801,012.50% UpsideITRMIterum Therapeutics 3.00Buy$9.00773.79% UpsideLIANLianBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AGRX, LIAN, ITRM, and ARTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/15/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.004/8/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/26/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$23.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.003/25/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGRXAgile Therapeutics$19.98M0.52N/AN/A($5.51) per share-0.27ARTVArtiva Biotherapeutics$250K155.90N/AN/A$7.68 per share0.21ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGRXAgile Therapeutics-$14.47M-$3.65N/A∞N/A-36.24%N/A-147.37%N/AARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%8/7/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ALatest AGRX, LIAN, ITRM, and ARTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGRXAgile TherapeuticsN/AN/AN/AN/AN/AARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGRXAgile TherapeuticsN/A0.560.38ARTVArtiva BiotherapeuticsN/A13.9313.93ITRMIterum TherapeuticsN/A3.723.58LIANLianBioN/A10.0610.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGRXAgile Therapeutics10.92%ARTVArtiva BiotherapeuticsN/AITRMIterum Therapeutics9.21%LIANLianBio74.85%Insider OwnershipCompanyInsider OwnershipAGRXAgile Therapeutics0.50%ARTVArtiva Biotherapeutics21.40%ITRMIterum Therapeutics9.20%LIANLianBio7.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGRXAgile Therapeutics306.86 million6.82 millionNot OptionableARTVArtiva Biotherapeutics8124.36 million19.15 millionN/AITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableAGRX, LIAN, ITRM, and ARTV HeadlinesRecent News About These CompaniesMeiraGTx Holdings PLCMay 3, 2025 | marketwatch.comWith Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisitionOctober 9, 2024 | fiercebiotech.comFChina's Zeekr prices US IPO at top of range to raise $441 millionMay 10, 2024 | msn.comExclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source saysMay 9, 2024 | msn.comWhy Is LianBio (LIAN) Stock Moving Today?March 15, 2024 | investorplace.comLianBio Announces Voluntarily Delisting from NasdaqFebruary 28, 2024 | globenewswire.comWith No Cure In Sight, Drugs Firm LianBio Begins Exit StrategyFebruary 23, 2024 | seekingalpha.comLianBio to shut down, return cash to investorsFebruary 14, 2024 | biopharmadive.comBLianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-MarketFebruary 13, 2024 | markets.businessinsider.comLianBio to Wind Down Operations, Declares Special DividendFebruary 13, 2024 | marketwatch.comLianBio Shares Gain After Co Announces Plans to Wind DownFebruary 13, 2024 | marketwatch.comLianBio Announces Completion of Strategic ReviewFebruary 13, 2024 | finance.yahoo.comB of A Securities Downgrades LianBio: Here's What You Need To KnowJanuary 3, 2024 | markets.businessinsider.comNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | markets.businessinsider.comLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | finance.yahoo.comInterest Is Growing for Smaller, More Speculative NamesDecember 20, 2023 | realmoney.thestreet.comLianBio Announces Departure of Chief Financial OfficerDecember 20, 2023 | finance.yahoo.comLianBio Names Stone as Interim CEO as Wang ResignsDecember 19, 2023 | marketwatch.comLianBio Announces Departure of Chief Executive OfficerDecember 19, 2023 | finance.yahoo.comLianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesDecember 6, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedRH Stock Rockets on Surprise Profit and Tariff ShiftBy Chris Markoch | June 15, 2025View RH Stock Rockets on Surprise Profit and Tariff ShiftAGRX, LIAN, ITRM, and ARTV Company DescriptionsAgile Therapeutics NASDAQ:AGRXAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Artiva Biotherapeutics NASDAQ:ARTV$1.60 -0.01 (-0.62%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.03 (+2.19%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Iterum Therapeutics NASDAQ:ITRM$1.03 +0.05 (+4.71%) Closing price 04:00 PM EasternExtended Trading$1.02 -0.01 (-0.49%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.LianBio NASDAQ:LIAN$0.42 +0.01 (+1.22%) As of 06/24/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
